Proteolysis of Tissue Factor Pathway Inhibitor (TFPI) by Plasmin: Effect on TFPI Activity

Anguo Li; Tze-Chein Wun

doi:10.1055/s-0037-1615224

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1998; 80(03): 423-427
DOI: 10.1055/s-0037-1615224

Rapid Communications

Schattauer GmbH

Proteolysis of Tissue Factor Pathway Inhibitor (TFPI) by Plasmin: Effect on TFPI Activity

Authors

Anguo Li

¹From Monsanto Co., St. Louis, MO, USA
Tze-Chein Wun

¹From Monsanto Co., St. Louis, MO, USA

Abstract

Summary

An important regulator of the initiation of blood coagulation is the plasma glycoprotein, tissue factor pathway inhibitor (TFPI). TFPI inhibits factor Xa and factor VIIa/tissue factor complex, thereby dampens the proteolytic cascade of the tissue factor pathway. Plasma clot lysis is primarily mediated by the fibrinolytic enzyme, plasmin, which is generated through limited proteolysis of plasminogen by endogenous or exogenously administered plaminogen activators. In this study, the interaction of plasmin with recombinant E. coli-derived TFPI (rTFPI) was examined. Plasmin was found to cause a time and concentration dependent proteolysis of rTFPI, resulting in the decrease of anti-factor Xa (measured by chromogenic substrate assay) and anticoagulant (measured by tissue factor-induced clotting assay) activities. Amino-terminal sequencing of the proteolytic fragments revealed that plasmin cleaved rTFPI at K86-T87, R107-G108, R199-A200, K249-G250, and K256-R257. Western blot analysis showed that proteolysis of exogenously added rTFPI also occurred in plasma supplemented with urokinase, and this is accompanied by decrease of anticoagulant activity. These changes were abolished by addition of aprotinin, an inhibitor of plasmin. These data indicate that TFPI is susceptible to proteolysis when plasma fibrinolytic system is activated. The results taken together suggest that plasmin degradation of TFPI may contribute to rethrombosis after thrombolysis, and may contribute to the variability of the efficacy of TFPI in various thrombolysis/reocclusion studies reported previously.

Full Text

References

References
1 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance and regulation. Biochemistry 1991; 30: 10363-70.
2 Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a prima ballerina. Thromb Haemost 1995; 79: 1-47.
3 Nemerson Y. The tissue factor pathway of blood coagulation. In: Hemostasis and Thrombosis: Basic principles and Clinical Practice. Third Edition. Colman RW, Hirsh J, Marder VJ, Salzman JB, eds. Lippincott PA. 1994 pp 81-93.
4 Broze Jr. GJ. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinol 1995; 6: 7-13.
5 Wun T-C, Kretzmer KK, Girard TJ, Miletich JP, Broze Jr. EG. Cloning and characterization of a cDNA coding for lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-4.
6 Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Meletich JP, Broze Jr. GJ. Functional significance of the Kunitz type inhibitory domains of lipoprotein associated coagulation inhibitor. Nature 1989; 338: 518-20.
7 Nordfang O, Bjorn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 1991; 30: 10371-6.
8 Wesselschmidt R, Likert K, Girard T, Wun T-C, Broze Jr. GJ. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of Factor Xa. Blood 1992; 79: 2004-10.
9 Wesselschmidt R, Likert K, Huang Z-F, MacPhail L, Broze Jr. GJ. Structural requirements for tissue factor pathway inhibitor interactions with Factor Xa and heparin. Blood Coagul Fibrinol 1993; 4: 661-9.
10 Lincoff AM, Topol EJ. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction?. Circulation 1993; 87: 1792-805.
11 Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch jr JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute artery thrombosis. Circulation 1992; 85: 805-15.
12 Haskel EJ, Torr SR, Day KC, Palmier MO, Wun T-C, Sobel BE, Abendschein DR. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor (LACI). Circulation 1991; 84: 821-7.
13 Abendschein DR, Meng YY, Torr-Brown S, Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995; 92: 944-9.
14 Kaiser B, Fareed J. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis. Thromb Haemost 1996; 76: 615-20.
15 Lefkovits J, Malycky JL, Rao JS, Hart CE, Plow EF, Topol EJ, Nicolini F. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. J Am Coll Cardiol 1996; 28: 1858-65.
16 Diaz-Collier JA, Palmier MO, Kretzmer KK, Bishop BF, Combs RG, Obukowicz MG, Frazier RB, Bild GS, Joy WD, Hill SR, Duffin ME, Gustafson ME, Junger JD, Grabner RW, Galluppi GR, Wun T-C. Refold and characterization of tissue factor pathway inhibitor expressed in Escherichia coli . Thromb Haemost 1994; 7: 339-46.
17 Broze Jr GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-46.
18 Marder VJ, Hirsh J, Bell WR. Rationale and practical basis of thrombolytic therapy. In: Hemostasis and Thrombosis: Basic priniciples and clinical practice. Third ed. Colman RW, Hirsh J, Marder VJ, Salzman JB. eds. Lippincott Co.; Philadelphia: 1994. pp. 1514-1541.
19 Wun T-C, Kretzmer KK, Palmier MO, Day KC, Huang MD, Welsch DJ, Lewis C, Wolfe RA, Zobel JF, Lang GW, Frazier RF, Bild GS, Peel MA, Shell RE, Horn NA, Junger KD, Foy BA, Gustafson ME, Leimgruber RM, Novotny WF, Broze Jr GJ, Pyla YE, Hippenmeyer PJ, Warren TG. Comparison of recombinant lipoprotein-associated coagulation inhibitors expressed in human SK hepatoma, mouse C127, baby hamster kidney, and Chinese hamster ovary cells. Thromb Haemost 1992; 68: 54-9.
20 Higuchi DA, Wun T-C, Likert KM, Broze Jr. GJ. The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 1992; 79: 1712-9.
21 Petersen LC, Bjorn SE, Nordfang O. Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost 1992; 67: 537-41.
22 Broze Jr GJ, Lange GW, Duffin KL, MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood coagul Fibrinol 1994; 5: 551-9.
23 Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-83.